Continuing Pharmacy Education / CE Master List / From the Mouths of Snakes: ACE Inhibitors
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

From the Mouths of Snakes: ACE Inhibitors

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation discusses Ace Inhibitors.

Learning Objectives

 1. Review pharmacological hypertension management history and ACE inhibitor discovery
2. Analyze ACE inhibitor mechanism of action and hypertension pathophysiology
3. Investigate approved and off-label uses of ACE inhibitors
4. Characterize ongoing ACE inhibitor research and potential benefits and uses

Session Offered

Released:  April 28, 2022
Expires:  April 28, 2025

Course Fee

$15 Pharmacist

ACPE UAN Codes

 0009-0000-22-020-H01-P

Session Code

22SR20-VXK92

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-020-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Alexandra Bieniek,
2022 PharmD Candidate
UConn School of Pharmacy
Storrs, CT

and

Jeannette Y. Wick, RPh, MBA FASCP
Director OPPD
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

Alexandra Bienieck and Jeannette Wick have no financial relationships with any ineligible company associated with these presentations.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Download

Post Test Pharmacist

1. How do ACE inhibitors work?
A. They convert angiotensin I to angiotensin II
B. They convert renin to angiotensin II
C. They convert Angiotensin II to angiotensin I

2. Before ACE inhibitors were marketed, what drugs were the mainstay of treatment for hypertension?
A. Injectable diuretics, especially furosemide
B. Oral diuretics, and especially chlorthalidone
C. Surgical interventions

3. Which of the following are FDA-approved uses for many ACE inhibitors?
A. Heart failure, hypertensive emergencies, MI and/or stroke prophylaxis
B. Heart Failure, hypertensive emergencies, MI and pancreatic cancer
C. Heart Failure, hypertensive emergencies, MI and sarcopenia

4. Which of the following indications are under investigation for ACE inhibitors?
A. Hepatic necrosis, oligospermia, and sarcopenia
B. Raynaud’s syndrome, sarcopenia, and oligospermia
C. Oligospermia, Raynaud’s syndrome, and sarcopenia.

5. In most conditions in which ACE inhibitors are being investigated but are not yet approved, what is the value of these drugs?
A. We have no treatments for many of these conditions, so ACE inhibitors would be valuable first-line options for people who are suffering
B. Many of these conditions have preferred treatments, ACE inhibitors may be valuable second- or third-line options for refractory cases
C. Many of these conditions have preferred treatments, but ACE inhibitors would replace the first-line treatments with fewer side effect